首页 > 最新文献

Neurotrauma reports最新文献

英文 中文
E-Bikes (Electrical Bicycles and Scooters) Related Neurosurgical Injuries in the Adult Population: A Single-Center Experience. 成人中与电动自行车(电动自行车和踏板车)相关的神经外科损伤:单中心经验。
Q3 CLINICAL NEUROLOGY Pub Date : 2023-11-16 eCollection Date: 2023-01-01 DOI: 10.1089/neur.2023.0071
Carla Richetta, Yevgeny Karepov

E-bikes (electrical bicycles and scooters) have been increasingly used as a means of transportation, especially among young adults. E-bikers have more accidents, at higher velocities and more severe kinematics, increasing the rate of neurosurgical injuries. Severe neurosurgical injury patterns result in significant morbidity and mortality. We collected data regarding adult patients (>18 years old), who suffered e-bike-related neurosurgical injuries, in a single tertiary medical center in Israel, between July 2019 and June 2020. Fifty-eight consecutive patients were included in this study. The average age was 34.9, and the average Glasgow Coma Scale (GCS) score upon admission was 13.2 and was significantly lower in operated patients (10.75). Fifty-four patients were riders; 51 (94.5%!) were not wearing a helmet. Fifty percent of patients had multiple types of trauma. Six patients suffered a spinal injury. Sixteen patients required either cranial or spinal surgery. Three patients died, and 1 remained in a vegetative state. Median Glasgow Outcome Scale-Extended (GOS-E) score at follow-up was 7.1. Operated patients stayed significantly longer in the intensive care unit (ICU) and in the hospital, and their GOS-E scores at discharge and follow-up were significantly lower. Most spinal injuries underwent surgery. Patients who wore helmets had significantly higher GCS scores and a shorter stay in the ICU and hospital. The unacceptable reality of the careless use of this transportation and the unique kinematics lead to severe neurosurgical injuries, comorbidities, and even mortality. Our results reflect the risks of e-bikes in the adult population. Most of our patients were in the mid-age group, and almost none had used a helmet. The results of this study highlight the potential need for neurosurgical treatment, and the need for long-term rehabilitation and follow-up, reflecting the emotional and financial toll of these injuries. Once again, this study showed that helmets save lives and emphasized the importance of protecting our heads.

电动自行车(电动自行车和踏板车)已经越来越多地被用作一种交通工具,尤其是在年轻人中。骑电动自行车的人有更多的事故,速度更快,运动更剧烈,增加了神经外科损伤的几率。严重的神经外科损伤模式导致显著的发病率和死亡率。我们收集了2019年7月至2020年6月期间在以色列一个三级医疗中心遭受电动自行车相关神经外科损伤的成年患者(>18岁)的数据。58例连续患者纳入本研究。平均年龄34.9岁,入院时格拉斯哥昏迷评分(GCS)平均为13.2分,手术患者的GCS评分明显低于住院患者(10.75分)。54名患者是骑手;51人(94.5%)未戴安全帽。50%的病人有多种创伤。6名患者出现脊髓损伤。16名患者需要颅脑或脊柱手术。3名患者死亡,1名仍处于植物人状态。随访时格拉斯哥结局扩展量表(GOS-E)评分中位数为7.1。手术患者在重症监护病房(ICU)和医院的住院时间明显延长,出院和随访时GOS-E评分明显降低。大多数脊柱损伤都进行了手术。戴头盔的患者GCS评分明显更高,在ICU和医院的住院时间也更短。不可接受的现实是,不小心使用这种运输和独特的运动学导致严重的神经外科损伤,合并症,甚至死亡。我们的研究结果反映了电动自行车在成年人中的风险。我们的大多数病人都是中年人,几乎没有人戴过头盔。这项研究的结果强调了神经外科治疗的潜在需求,以及长期康复和随访的需求,反映了这些损伤的情感和经济代价。这项研究再次表明,头盔可以挽救生命,并强调了保护我们头部的重要性。
{"title":"E-Bikes (Electrical Bicycles and Scooters) Related Neurosurgical Injuries in the Adult Population: A Single-Center Experience.","authors":"Carla Richetta, Yevgeny Karepov","doi":"10.1089/neur.2023.0071","DOIUrl":"https://doi.org/10.1089/neur.2023.0071","url":null,"abstract":"<p><p>E-bikes (electrical bicycles and scooters) have been increasingly used as a means of transportation, especially among young adults. E-bikers have more accidents, at higher velocities and more severe kinematics, increasing the rate of neurosurgical injuries. Severe neurosurgical injury patterns result in significant morbidity and mortality. We collected data regarding adult patients (>18 years old), who suffered e-bike-related neurosurgical injuries, in a single tertiary medical center in Israel, between July 2019 and June 2020. Fifty-eight consecutive patients were included in this study. The average age was 34.9, and the average Glasgow Coma Scale (GCS) score upon admission was 13.2 and was significantly lower in operated patients (10.75). Fifty-four patients were riders; 51 (94.5%!) were not wearing a helmet. Fifty percent of patients had multiple types of trauma. Six patients suffered a spinal injury. Sixteen patients required either cranial or spinal surgery. Three patients died, and 1 remained in a vegetative state. Median Glasgow Outcome Scale-Extended (GOS-E) score at follow-up was 7.1. Operated patients stayed significantly longer in the intensive care unit (ICU) and in the hospital, and their GOS-E scores at discharge and follow-up were significantly lower. Most spinal injuries underwent surgery. Patients who wore helmets had significantly higher GCS scores and a shorter stay in the ICU and hospital. The unacceptable reality of the careless use of this transportation and the unique kinematics lead to severe neurosurgical injuries, comorbidities, and even mortality. Our results reflect the risks of e-bikes in the adult population. Most of our patients were in the mid-age group, and almost none had used a helmet. The results of this study highlight the potential need for neurosurgical treatment, and the need for long-term rehabilitation and follow-up, reflecting the emotional and financial toll of these injuries. Once again, this study showed that helmets save lives and emphasized the importance of protecting our heads.</p>","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":"4 1","pages":"797-804"},"PeriodicalIF":0.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138464902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Research Protocol to Study the Priming Effects of Breathing Low Oxygen on Enhancing Training-Related Gains in Walking Function for Persons With Spinal Cord Injury: The BO2ST Trial. 研究低氧呼吸对脊髓损伤患者步行功能增强的启动效应的研究方案:BO2ST试验。
Q3 CLINICAL NEUROLOGY Pub Date : 2023-11-06 eCollection Date: 2023-01-01 DOI: 10.1089/neur.2023.0036
William M Muter, Linda Mansson, Christopher Tuthill, Shreya Aalla, Stella Barth, Emily Evans, Kelly McKenzie, Sara Prokup, Chen Yang, Milap Sandhu, W Zev Rymer, Victor R Edgerton, Parag Gad, Gordon S Mitchell, Samuel S Wu, Guogen Shan, Arun Jayaraman, Randy D Trumbower

Brief episodes of low oxygen breathing (therapeutic acute intermittent hypoxia; tAIH) may serve as an effective plasticity-promoting primer to enhance the effects of transcutaneous spinal stimulation-enhanced walking therapy (WALKtSTIM) in persons with chronic (>1 year) spinal cord injury (SCI). Pre-clinical studies in rodents with SCI show that tAIH and WALKtSTIM therapies harness complementary mechanisms of plasticity to maximize walking recovery. Here, we present a multi-site clinical trial protocol designed to examine the influence of tAIH + WALKtSTIM on walking recovery in persons with chronic SCI. We hypothesize that daily (eight sessions, 2 weeks) tAIH + WALKtSTIM will elicit faster, more persistent improvements in walking recovery than either treatment alone. To test our hypothesis, we are conducting a placebo-controlled clinical trial on 60 SCI participants who randomly receive one of three interventions: tAIH + WALKtSTIM; Placebo + WALKtSTIM; and tAIH + WALKtSHAM. Participants receive daily tAIH (fifteen 90-sec episodes at 10% O2 with 60-sec intervals at 21% O2) or daily placebo (fifteen 90-sec episodes at 21% O2 with 60-sec intervals at 21% O2) before a 45-min session of WALKtSTIM or WALKtSHAM. Our primary outcome measures assess walking speed (10-Meter Walk Test), endurance (6-Minute Walk Test), and balance (Timed Up and Go Test). For safety, we also measure pain levels, spasticity, sleep behavior, cognition, and rates of systemic hypertension and autonomic dysreflexia. Assessments occur before, during, and after sessions, as well as at 1, 4, and 8 weeks post-intervention. Results from this study extend our understanding of the functional benefits of tAIH priming by investigating its capacity to boost the neuromodulatory effects of transcutaneous spinal stimulation on restoring walking after SCI. Given that there is no known cure for SCI and no single treatment is sufficient to overcome walking deficits, there is a critical need for combinatorial treatments that accelerate and anchor walking gains in persons with lifelong SCI.

Trial registration: ClinicalTrials.gov, NCT05563103.

短暂的低氧呼吸发作(治疗性急性间歇缺氧;tAIH)可能作为一种有效的可塑性促进引物,以增强慢性(>1年)脊髓损伤(SCI)患者经皮脊髓刺激增强步行治疗(WALKtSTIM)的效果。对脊髓损伤啮齿动物的临床前研究表明,tAIH和WALKtSTIM疗法利用可塑性的互补机制来最大限度地恢复行走。在这里,我们提出了一项多地点临床试验方案,旨在研究tAIH + WALKtSTIM对慢性脊髓损伤患者行走恢复的影响。我们假设每天(8次,2周)tAIH + WALKtSTIM比单独治疗更能促进步行恢复的更快、更持久的改善。为了验证我们的假设,我们正在对60名SCI参与者进行一项安慰剂对照临床试验,他们随机接受三种干预措施之一:tAIH + WALKtSTIM;安慰剂+ WALKtSTIM;和tAIH + WALKtSHAM。参与者在进行45分钟的WALKtSTIM或WALKtSHAM治疗前,每天接受tAIH治疗(15次90秒,10%氧气,间隔60秒,21%氧气)或安慰剂治疗(15次90秒,21%氧气,间隔60秒,21%氧气)。我们的主要结果测量评估步行速度(10米步行测试),耐力(6分钟步行测试)和平衡(计时起来和走测试)。为了安全起见,我们还测量了疼痛水平、痉挛、睡眠行为、认知、全身性高血压和自主神经反射障碍的发生率。评估在治疗前、治疗中、治疗后以及干预后1周、4周和8周进行。本研究的结果扩展了我们对tAIH启动的功能益处的理解,通过研究其增强经皮脊髓刺激对脊髓损伤后恢复行走的神经调节作用的能力。鉴于目前还没有已知的治愈脊髓损伤的方法,也没有单一的治疗方法足以克服行走缺陷,因此迫切需要联合治疗来加速和固定终身脊髓损伤患者的行走能力。试验注册:ClinicalTrials.gov, NCT05563103。
{"title":"A Research Protocol to Study the Priming Effects of Breathing Low Oxygen on Enhancing Training-Related Gains in Walking Function for Persons With Spinal Cord Injury: The BO<sub>2</sub>ST Trial.","authors":"William M Muter, Linda Mansson, Christopher Tuthill, Shreya Aalla, Stella Barth, Emily Evans, Kelly McKenzie, Sara Prokup, Chen Yang, Milap Sandhu, W Zev Rymer, Victor R Edgerton, Parag Gad, Gordon S Mitchell, Samuel S Wu, Guogen Shan, Arun Jayaraman, Randy D Trumbower","doi":"10.1089/neur.2023.0036","DOIUrl":"https://doi.org/10.1089/neur.2023.0036","url":null,"abstract":"<p><p>Brief episodes of low oxygen breathing (therapeutic acute intermittent hypoxia; tAIH) may serve as an effective plasticity-promoting primer to enhance the effects of transcutaneous spinal stimulation-enhanced walking therapy (WALK<sub>tSTIM</sub>) in persons with chronic (>1 year) spinal cord injury (SCI). Pre-clinical studies in rodents with SCI show that tAIH and WALK<sub>tSTIM</sub> therapies harness complementary mechanisms of plasticity to maximize walking recovery. Here, we present a multi-site clinical trial protocol designed to examine the influence of tAIH + WALK<sub>tSTIM</sub> on walking recovery in persons with chronic SCI. We hypothesize that daily (eight sessions, 2 weeks) tAIH + WALK<sub>tSTIM</sub> will elicit faster, more persistent improvements in walking recovery than either treatment alone. To test our hypothesis, we are conducting a placebo-controlled clinical trial on 60 SCI participants who randomly receive one of three interventions: tAIH + WALK<sub>tSTIM</sub>; Placebo + WALK<sub>tSTIM</sub>; and tAIH + WALK<sub>tSHAM</sub>. Participants receive daily tAIH (fifteen 90-sec episodes at 10% O<sub>2</sub> with 60-sec intervals at 21% O<sub>2</sub>) or daily placebo (fifteen 90-sec episodes at 21% O<sub>2</sub> with 60-sec intervals at 21% O<sub>2</sub>) before a 45-min session of WALK<sub>tSTIM</sub> or WALK<sub>tSHAM</sub>. Our primary outcome measures assess walking speed (10-Meter Walk Test), endurance (6-Minute Walk Test), and balance (Timed Up and Go Test). For safety, we also measure pain levels, spasticity, sleep behavior, cognition, and rates of systemic hypertension and autonomic dysreflexia. Assessments occur before, during, and after sessions, as well as at 1, 4, and 8 weeks post-intervention. Results from this study extend our understanding of the functional benefits of tAIH priming by investigating its capacity to boost the neuromodulatory effects of transcutaneous spinal stimulation on restoring walking after SCI. Given that there is no known cure for SCI and no single treatment is sufficient to overcome walking deficits, there is a critical need for combinatorial treatments that accelerate and anchor walking gains in persons with lifelong SCI.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov, NCT05563103.</p>","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":"4 1","pages":"736-750"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10659019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138464901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation of Insulin-Like Growth Factor 1 With Cognitive Functions in Mild Traumatic Brain Injury Patients 胰岛素样生长因子1与轻度外伤性脑损伤患者认知功能的相关性
Q3 CLINICAL NEUROLOGY Pub Date : 2023-11-01 DOI: 10.1089/neur.2023.0085
Ju-Chi Ou, Yin-Hsun Feng, Kai-Yun Chen, Yung-Hsiao Chiang, Tsung-I Hsu, Chung-Che Wu
Mild traumatic brain injury (mTBI) is a prevalent health concern with variable recovery trajectories, necessitating reliable prognostic markers. Insulin-like growth factor 1 (IGF-1) emerges as a potential candidate because of its role in cellular growth, repair, and neuroprotection. However, limited studies investigate IGF-1 as a prognostic marker in mTBI patients. This study aimed to explore the correlation of IGF-1 with cognitive functions assessed using the Wisconsin Card Sorting Test (WCST) in mTBI patients. We analyzed data from 295 mTBI and 200 healthy control participants, assessing demographic characteristics, injury causes, and IGF-1 levels. Cognitive functions were evaluated using the WCST. Correlation analyses and regression models were used to investigate the associations between IGF-1 levels, demographic factors, and WCST scores. Significant differences were observed between mTBI and control groups in the proportion of females and average education years. Falls and traffic accidents were identified as the primary causes of mTBI. The mTBI group demonstrated worse cognitive outcomes on the WCST, except for the “Learning to Learn” index. Correlation analyses revealed significant relationships between IGF-1 levels, demographic factors, and specific WCST scores. Regression models demonstrated that IGF-1, age, and education years significantly influenced various WCST scores, suggesting their roles as potential prognostic markers for cognitive outcomes in mTBI patients. We provide valuable insights into the potential correlation of IGF-1 with cognitive functions in mTBI patients, particularly in tasks requiring cognitive flexibility and problem solving.
轻度创伤性脑损伤(mTBI)是一种普遍存在的健康问题,其恢复轨迹多变,需要可靠的预后标志物。胰岛素样生长因子1 (IGF-1)因其在细胞生长、修复和神经保护中的作用而成为潜在的候选者。然而,很少有研究将IGF-1作为mTBI患者的预后指标。本研究旨在探讨IGF-1与mTBI患者认知功能的相关性,采用威斯康星卡片分类测验(WCST)评估。我们分析了295名mTBI参与者和200名健康对照者的数据,评估了人口统计学特征、损伤原因和IGF-1水平。使用WCST评估认知功能。使用相关分析和回归模型来研究IGF-1水平、人口统计学因素和WCST评分之间的关系。mTBI组与对照组在女性比例和平均受教育年限上存在显著差异。跌倒和交通事故被确定为mTBI的主要原因。除了“学会学习”指数外,mTBI组在WCST上表现出更差的认知结果。相关分析显示IGF-1水平、人口统计学因素和特定WCST评分之间存在显著关系。回归模型显示,IGF-1、年龄和受教育年限显著影响各种WCST评分,表明它们是mTBI患者认知结局的潜在预后指标。我们为IGF-1与mTBI患者认知功能的潜在相关性提供了有价值的见解,特别是在需要认知灵活性和解决问题的任务中。
{"title":"Correlation of Insulin-Like Growth Factor 1 With Cognitive Functions in Mild Traumatic Brain Injury Patients","authors":"Ju-Chi Ou, Yin-Hsun Feng, Kai-Yun Chen, Yung-Hsiao Chiang, Tsung-I Hsu, Chung-Che Wu","doi":"10.1089/neur.2023.0085","DOIUrl":"https://doi.org/10.1089/neur.2023.0085","url":null,"abstract":"Mild traumatic brain injury (mTBI) is a prevalent health concern with variable recovery trajectories, necessitating reliable prognostic markers. Insulin-like growth factor 1 (IGF-1) emerges as a potential candidate because of its role in cellular growth, repair, and neuroprotection. However, limited studies investigate IGF-1 as a prognostic marker in mTBI patients. This study aimed to explore the correlation of IGF-1 with cognitive functions assessed using the Wisconsin Card Sorting Test (WCST) in mTBI patients. We analyzed data from 295 mTBI and 200 healthy control participants, assessing demographic characteristics, injury causes, and IGF-1 levels. Cognitive functions were evaluated using the WCST. Correlation analyses and regression models were used to investigate the associations between IGF-1 levels, demographic factors, and WCST scores. Significant differences were observed between mTBI and control groups in the proportion of females and average education years. Falls and traffic accidents were identified as the primary causes of mTBI. The mTBI group demonstrated worse cognitive outcomes on the WCST, except for the “Learning to Learn” index. Correlation analyses revealed significant relationships between IGF-1 levels, demographic factors, and specific WCST scores. Regression models demonstrated that IGF-1, age, and education years significantly influenced various WCST scores, suggesting their roles as potential prognostic markers for cognitive outcomes in mTBI patients. We provide valuable insights into the potential correlation of IGF-1 with cognitive functions in mTBI patients, particularly in tasks requiring cognitive flexibility and problem solving.","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":"44 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135564265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization of Traumatic Brain Injury in a Gyrencephalic Ferret Model Using the Novel Closed Head Injury Model of Engineered Rotational Acceleration (CHIMERA) 利用新型工程旋转加速度闭合性脑损伤模型(CHIMERA)表征脑白头雪貂创伤性脑损伤模型
Q3 CLINICAL NEUROLOGY Pub Date : 2023-11-01 DOI: 10.1089/neur.2023.0047
Justin L. Krieg, Anna V. Leonard, Renee J. Tuner, Frances Corrigan
Traumatic brain injury (TBI) results from mechanical force to the brain and leads to a series of biochemical responses that further damage neurons and supporting cells. Clinically, most TBIs result from an impact to the intact skull, making closed head TBI pre-clinical models highly relevant. However, most of these closed head TBI models use lissencephalic rodents, which may not transduce biomechanical load in the same manner as gyrencephalic humans. To address this translational gap, this study aimed to characterize acute axonal injury and microglial responses in ferrets—the smallest gyrencephalic mammal. Injury was induced in male ferrets (Mustela furo; 1.20–1.51 kg; 6–9 months old) with the novel Closed Head Injury Model of Engineered Rotational Acceleration (CHIMERA) model. Animals were randomly allocated to either sham (n = 4), a 22J (joules) impact (n = 4), or a 27J impact (n = 4). Axonal injury was examined histologically with amyloid precursor protein (APP), neurofilament M (RMO 14.9) (RMO-14), and phosphorylated tau (AT180) and the microglial response with ionized calcium-binding adaptor molecule 1 at 24 h post-injury in gray and white matter regions. Graded axonal injury was observed with modest increases in APP and RMO-14 immunoreactivity in the 22J TBI group, mostly within the corpus callosum and fornix and more extensive diffuse axonal injury encompassing gray matter structures like the thalamus and hypothalamus in the 27J group. Accompanying microglial activation was only observed in the 27J group, most prominently within the white matter tracts in response to the larger amounts of axonal injury. The 27J, but not the 22J, group showed an increase in AT180 within the base of the sulci post-injury. This could suggest that the strain may be highest in this region, demonstrating the different responses in gyrencephalic compared to lissencephalic brains. The CHIMERA model in ferrets mimic many of the histopathological features of human closed head TBI acutely and provides a promising model to investigate the pathophysiology of TBI.
创伤性脑损伤(TBI)是由机械力作用于大脑引起的,并导致一系列生化反应,进一步损害神经元和支持细胞。临床上,大多数脑损伤是由于对完整颅骨的冲击造成的,这使得闭合性脑损伤临床前模型具有很高的相关性。然而,大多数闭式脑损伤模型使用的是无脑啮齿动物,它们可能不会以与脑回动物相同的方式传递生物力学载荷。为了解决这一翻译空白,本研究旨在表征雪貂(最小的脑回哺乳动物)的急性轴突损伤和小胶质细胞反应。雄性雪貂(Mustela furo;1.20 - -1.51公斤;6-9个月大的婴儿)使用新型的封闭头部损伤模型的工程旋转加速度(CHIMERA)模型。动物被随机分配到假手术组(n = 4)、22J(焦耳)撞击组(n = 4)和27J撞击组(n = 4)。用淀粉样蛋白前体蛋白(APP)、神经丝M (RMO 14.9) (RMO-14)和磷酸化tau (AT180)检测轴突损伤,并在损伤后24小时在灰质和白质区域用离子钙结合接头分子1观察小胶质细胞的反应。在22J脑损伤组中,APP和RMO-14免疫反应性轻度增加,主要发生在胼胝体和穹窿内,而在27J脑损伤组中,更广泛的弥漫性轴索损伤包括丘脑和下丘脑等灰质结构。伴随的小胶质细胞激活仅在27J组中观察到,最明显的是在白质束中对大量轴突损伤做出反应。27J组损伤后脑沟底部的AT180增加,而22J组则没有。这可能表明该菌株可能在该区域最高,表明脑回畸形与无脑畸形大脑的反应不同。雪貂CHIMERA模型能较好地模拟人类闭合性脑损伤的许多组织病理特征,为研究脑损伤的病理生理学提供了一种有前景的模型。
{"title":"Characterization of Traumatic Brain Injury in a Gyrencephalic Ferret Model Using the Novel Closed Head Injury Model of Engineered Rotational Acceleration (CHIMERA)","authors":"Justin L. Krieg, Anna V. Leonard, Renee J. Tuner, Frances Corrigan","doi":"10.1089/neur.2023.0047","DOIUrl":"https://doi.org/10.1089/neur.2023.0047","url":null,"abstract":"Traumatic brain injury (TBI) results from mechanical force to the brain and leads to a series of biochemical responses that further damage neurons and supporting cells. Clinically, most TBIs result from an impact to the intact skull, making closed head TBI pre-clinical models highly relevant. However, most of these closed head TBI models use lissencephalic rodents, which may not transduce biomechanical load in the same manner as gyrencephalic humans. To address this translational gap, this study aimed to characterize acute axonal injury and microglial responses in ferrets—the smallest gyrencephalic mammal. Injury was induced in male ferrets (Mustela furo; 1.20–1.51 kg; 6–9 months old) with the novel Closed Head Injury Model of Engineered Rotational Acceleration (CHIMERA) model. Animals were randomly allocated to either sham (n = 4), a 22J (joules) impact (n = 4), or a 27J impact (n = 4). Axonal injury was examined histologically with amyloid precursor protein (APP), neurofilament M (RMO 14.9) (RMO-14), and phosphorylated tau (AT180) and the microglial response with ionized calcium-binding adaptor molecule 1 at 24 h post-injury in gray and white matter regions. Graded axonal injury was observed with modest increases in APP and RMO-14 immunoreactivity in the 22J TBI group, mostly within the corpus callosum and fornix and more extensive diffuse axonal injury encompassing gray matter structures like the thalamus and hypothalamus in the 27J group. Accompanying microglial activation was only observed in the 27J group, most prominently within the white matter tracts in response to the larger amounts of axonal injury. The 27J, but not the 22J, group showed an increase in AT180 within the base of the sulci post-injury. This could suggest that the strain may be highest in this region, demonstrating the different responses in gyrencephalic compared to lissencephalic brains. The CHIMERA model in ferrets mimic many of the histopathological features of human closed head TBI acutely and provides a promising model to investigate the pathophysiology of TBI.","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":"261 1-4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135566382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Perspectives on Data Sharing in Persons With Spinal Cord Injury 脊髓损伤患者数据共享的展望
Q3 CLINICAL NEUROLOGY Pub Date : 2023-11-01 DOI: 10.1089/neur.2023.0035
Freda M. Warner, Bobo Tong, Jessie McDougall, Kathleen A. Martin Ginis, Alexander G. Rabchevsky, Jacquelyn J. Cragg, John L.K. Kramer
Open data sharing of clinical research aims to improve transparency and support novel scientific discoveries. There are also risks, including participant identification and the potential for stigmatization. The perspectives of persons participating in research are needed to inform open data-sharing policies. The aim of the current study was to determine perspectives on data sharing in persons with spinal cord injury (SCI), including risks and benefits, and types of data people are most willing to share. A secondary aim was to examine predictors of willingness to share data. Persons with SCIs in the United States and Canada completed a survey developed and disseminated through various channels, including our community partner, the North American Spinal Cord Injury Consortium. The study collected data from 232 participants, with 52.2% from Canada and 42.2% from the United States, and the majority completed the survey in English. Most participants had previously participated in research and had been living with an SCI for ≥5 years. Overall, most participants reported that the potential benefits of data sharing outweighed the negatives, with persons with SCI seen as the most trustworthy partners for data sharing. The highest levels of concern were that information could be stolen and companies might use the information for marketing purposes. Persons with SCI were generally supportive of data sharing for research purposes. Clinical trials should consider including a statement on open data sharing in informed consents to better acknowledge the contribution of research participants in future studies.
临床研究的开放数据共享旨在提高透明度并支持新的科学发现。也存在风险,包括参与者身份识别和污名化的可能性。参与研究人员的观点需要为开放数据共享政策提供信息。当前研究的目的是确定脊髓损伤(SCI)患者数据共享的观点,包括风险和收益,以及人们最愿意共享的数据类型。第二个目的是检验共享数据意愿的预测因素。美国和加拿大的脊髓损伤患者完成了一项调查,该调查通过各种渠道进行了开发和传播,包括我们的社区合作伙伴北美脊髓损伤协会。该研究收集了232名参与者的数据,其中52.2%来自加拿大,42.2%来自美国,大多数人用英语完成了调查。大多数参与者以前参加过研究,并且患有SCI≥5年。总体而言,大多数参与者报告说,数据共享的潜在好处大于坏处,SCI患者被视为数据共享最值得信赖的伙伴。最令人担忧的是,信息可能被盗,公司可能将这些信息用于营销目的。SCI患者通常支持为研究目的共享数据。临床试验应考虑在知情同意书中加入关于开放数据共享的声明,以更好地承认研究参与者在未来研究中的贡献。
{"title":"Perspectives on Data Sharing in Persons With Spinal Cord Injury","authors":"Freda M. Warner, Bobo Tong, Jessie McDougall, Kathleen A. Martin Ginis, Alexander G. Rabchevsky, Jacquelyn J. Cragg, John L.K. Kramer","doi":"10.1089/neur.2023.0035","DOIUrl":"https://doi.org/10.1089/neur.2023.0035","url":null,"abstract":"Open data sharing of clinical research aims to improve transparency and support novel scientific discoveries. There are also risks, including participant identification and the potential for stigmatization. The perspectives of persons participating in research are needed to inform open data-sharing policies. The aim of the current study was to determine perspectives on data sharing in persons with spinal cord injury (SCI), including risks and benefits, and types of data people are most willing to share. A secondary aim was to examine predictors of willingness to share data. Persons with SCIs in the United States and Canada completed a survey developed and disseminated through various channels, including our community partner, the North American Spinal Cord Injury Consortium. The study collected data from 232 participants, with 52.2% from Canada and 42.2% from the United States, and the majority completed the survey in English. Most participants had previously participated in research and had been living with an SCI for ≥5 years. Overall, most participants reported that the potential benefits of data sharing outweighed the negatives, with persons with SCI seen as the most trustworthy partners for data sharing. The highest levels of concern were that information could be stolen and companies might use the information for marketing purposes. Persons with SCI were generally supportive of data sharing for research purposes. Clinical trials should consider including a statement on open data sharing in informed consents to better acknowledge the contribution of research participants in future studies.","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":"90 6","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135564724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retrospective Observational Study of Patients With Subdural Hematoma Treated With Idarucizumab 依达鲁珠单抗治疗硬膜下血肿患者的回顾性观察研究
Q3 CLINICAL NEUROLOGY Pub Date : 2023-11-01 DOI: 10.1089/neur.2023.0065
Eiichi Suehiro, Hideyuki Ishihara, Yohei Kogeichi, Tsunenori Ozawa, Koichi Haraguchi, Masaru Honda, Yumie Honda, Makoto Inaba, Ryusuke Kabeya, Naoaki Kanda, Kenta Koketsu, Nobukuni Murakami, Hidetoshi Nakamoto, Kotaro Oshio, Kuniyasu Saigusa, Takashi Shuto, Shuichi Sugiyama, Kenji Suzuyama, Tsuguaki Terashima, Mitsuharu Tsuura, Mitsutoshi Nakada, Hitoshi Kobata, Toshio Higashi, Nobuyuki Sakai, Michiyasu Suzuki
Use of anticoagulants is increasing with the aging of societies. The safe first-line drug is likely to be a direct oral anticoagulant (DOAC), but outcomes of treatment of traumatic brain injury (TBI) with anticoagulants are uncertain. Therefore, we examined the clinical effect of idarucizumab as reversal therapy in elderly patients with TBI who were treated with dabigatran. A retrospective multi-center observational study was performed in patients ≥65 years of age who developed acute traumatic subdural hematoma during treatment with dabigatran and underwent reversal therapy with idarucizumab. The items examined included patient background, neurological and imaging findings at arrival, course after admission, complications, and outcomes. A total of 23 patients were enrolled in the study. The patients had a mean age of 78.9 years. Cause of TBI was fall in 60.9% of the subjects. Mean Glasgow Coma Scale score at arrival was 8.7; anisocoria was present in 31.8% of cases. Exacerbation of consciousness was found in 30.4%, but only in 13.3% of subjects treated with idarucizumab before consciousness and imaging findings worsened. Dabigatran was discontinued in 81.8% of cases after hematoma development, with a mean withdrawal period of 12.1 days. The favorable outcome rate was 21.7%, and mortality was 39.1%. In multi-variate analysis, timing of idarucizumab administration was associated with a favorable outcome. There were ischemic complications in 3 cases (13.1%), and all three events occurred ≥7 days after administration of idarucizumab. These findings suggest that in cases that develop hematoma during treatment with dabigatran, it is important to administer idarucizumab early and restart dabigatran after conditions stabilize.
抗凝血剂的使用随着社会的老龄化而增加。安全的一线药物可能是直接口服抗凝剂(DOAC),但使用抗凝剂治疗创伤性脑损伤(TBI)的结果尚不确定。因此,我们研究了idarucizumab作为逆转疗法在接受达比加群治疗的老年TBI患者中的临床效果。一项回顾性多中心观察性研究对≥65岁、在达比加群治疗期间出现急性外伤性硬膜下血肿并接受依达鲁单抗逆转治疗的患者进行了研究。检查的项目包括患者背景、到达时的神经学和影像学发现、入院后的病程、并发症和结果。共有23名患者参加了这项研究。患者的平均年龄为78.9岁。60.9%的受试者发生TBI的原因为跌倒。到达时格拉斯哥昏迷评分平均为8.7分;31.8%的病例存在异色性。30.4%的患者意识恶化,但在接受依达鲁珠单抗治疗的患者中,在意识和影像学表现恶化之前,意识恶化仅占13.3%。81.8%的血肿患者停药达比加群,平均停药期为12.1天。良好转归率为21.7%,死亡率为39.1%。在多变量分析中,idarucizumab给药的时机与有利的结果相关。3例(13.1%)出现缺血性并发症,这3例事件均发生在给予依达鲁珠单抗后≥7天。这些发现表明,在使用达比加群治疗期间出现血肿的病例中,早期给药依达鲁单抗并在病情稳定后重新使用达比加群是很重要的。
{"title":"Retrospective Observational Study of Patients With Subdural Hematoma Treated With Idarucizumab","authors":"Eiichi Suehiro, Hideyuki Ishihara, Yohei Kogeichi, Tsunenori Ozawa, Koichi Haraguchi, Masaru Honda, Yumie Honda, Makoto Inaba, Ryusuke Kabeya, Naoaki Kanda, Kenta Koketsu, Nobukuni Murakami, Hidetoshi Nakamoto, Kotaro Oshio, Kuniyasu Saigusa, Takashi Shuto, Shuichi Sugiyama, Kenji Suzuyama, Tsuguaki Terashima, Mitsuharu Tsuura, Mitsutoshi Nakada, Hitoshi Kobata, Toshio Higashi, Nobuyuki Sakai, Michiyasu Suzuki","doi":"10.1089/neur.2023.0065","DOIUrl":"https://doi.org/10.1089/neur.2023.0065","url":null,"abstract":"Use of anticoagulants is increasing with the aging of societies. The safe first-line drug is likely to be a direct oral anticoagulant (DOAC), but outcomes of treatment of traumatic brain injury (TBI) with anticoagulants are uncertain. Therefore, we examined the clinical effect of idarucizumab as reversal therapy in elderly patients with TBI who were treated with dabigatran. A retrospective multi-center observational study was performed in patients ≥65 years of age who developed acute traumatic subdural hematoma during treatment with dabigatran and underwent reversal therapy with idarucizumab. The items examined included patient background, neurological and imaging findings at arrival, course after admission, complications, and outcomes. A total of 23 patients were enrolled in the study. The patients had a mean age of 78.9 years. Cause of TBI was fall in 60.9% of the subjects. Mean Glasgow Coma Scale score at arrival was 8.7; anisocoria was present in 31.8% of cases. Exacerbation of consciousness was found in 30.4%, but only in 13.3% of subjects treated with idarucizumab before consciousness and imaging findings worsened. Dabigatran was discontinued in 81.8% of cases after hematoma development, with a mean withdrawal period of 12.1 days. The favorable outcome rate was 21.7%, and mortality was 39.1%. In multi-variate analysis, timing of idarucizumab administration was associated with a favorable outcome. There were ischemic complications in 3 cases (13.1%), and all three events occurred ≥7 days after administration of idarucizumab. These findings suggest that in cases that develop hematoma during treatment with dabigatran, it is important to administer idarucizumab early and restart dabigatran after conditions stabilize.","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":"235 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135566163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antipsychotic Drugs: The Antithesis to Neurorehabilitation in Models of Pre-Clinical Traumatic Brain Injury. 抗精神病药物:临床前创伤性脑损伤模型中神经康复的拮抗剂。
IF 1.8 Q3 CLINICAL NEUROLOGY Pub Date : 2023-10-31 eCollection Date: 2023-01-01 DOI: 10.1089/neur.2023.0082
Nicholas S Race, Eleni H Moschonas, Jeffrey P Cheng, Corina O Bondi, Anthony E Kline

Sixty-nine million traumatic brain injuries (TBIs) are reported worldwide each year, and, of those, close to 3 million occur in the United States. In addition to neurobehavioral and cognitive deficits, TBI induces other maladaptive behaviors, such as agitation and aggression, which must be managed for safe, accurate assessment and effective treatment of the patient. The use of antipsychotic drugs (APDs) in TBI is supported by some expert guidelines, which suggests that they are an important part of the pharmacological armamentarium to be used in the management of agitation. Despite the advantages of APDs after TBI, there are significant disadvantages that may not be fully appreciated clinically during decision making because of the lack of a readily available updated compendium. Hence, the aim of this review is to integrate the existing findings and present the current state of APD use in pre-clinical models of TBI. The studies discussed were identified through PubMed and the University of Pittsburgh Library System search strategies and reveal that APDs, particularly those with dopamine2 (D2) receptor antagonism, generally impair the recovery process in rodents of both sexes and, in some instances, attenuate the potential benefits of neurorehabilitation. We believe that the compilation of findings represented by this exhaustive review of pre-clinical TBI + APD models can serve as a convenient source for guiding informed decisions by critical care clinicians and physiatrists contemplating APD use for patients exhibiting agitation.

据报道,全世界每年有6900万例创伤性脑损伤,其中近300万例发生在美国。除了神经行为和认知缺陷外,TBI还会诱发其他适应不良行为,如激动和攻击,必须对这些行为进行管理,以便对患者进行安全、准确的评估和有效的治疗。抗精神病药物(APD)在创伤性脑损伤中的使用得到了一些专家指南的支持,这表明它们是用于治疗躁动的药理学药物的重要组成部分。尽管TBI后APD具有优势,但由于缺乏现成的更新简编,在决策过程中,临床上可能无法充分认识到其显著的缺点。因此,本综述的目的是整合现有研究结果,并介绍APD在TBI临床前模型中的应用现状。所讨论的研究是通过PubMed和匹兹堡大学图书馆系统的搜索策略确定的,并表明APD,特别是那些具有多巴胺2(D2)受体拮抗作用的APD,通常会损害两性啮齿动物的恢复过程,在某些情况下,会削弱神经康复的潜在益处。我们相信,这篇对临床前TBI+APD模型的详尽综述所代表的研究结果汇编,可以作为指导重症监护临床医生和物理治疗师做出知情决策的方便来源,这些临床医生和物理学家考虑将APD用于表现出激动的患者。
{"title":"Antipsychotic Drugs: The Antithesis to Neurorehabilitation in Models of Pre-Clinical Traumatic Brain Injury.","authors":"Nicholas S Race, Eleni H Moschonas, Jeffrey P Cheng, Corina O Bondi, Anthony E Kline","doi":"10.1089/neur.2023.0082","DOIUrl":"10.1089/neur.2023.0082","url":null,"abstract":"<p><p>Sixty-nine million traumatic brain injuries (TBIs) are reported worldwide each year, and, of those, close to 3 million occur in the United States. In addition to neurobehavioral and cognitive deficits, TBI induces other maladaptive behaviors, such as agitation and aggression, which must be managed for safe, accurate assessment and effective treatment of the patient. The use of antipsychotic drugs (APDs) in TBI is supported by some expert guidelines, which suggests that they are an important part of the pharmacological armamentarium to be used in the management of agitation. Despite the advantages of APDs after TBI, there are significant disadvantages that may not be fully appreciated clinically during decision making because of the lack of a readily available updated compendium. Hence, the aim of this review is to integrate the existing findings and present the current state of APD use in pre-clinical models of TBI. The studies discussed were identified through PubMed and the University of Pittsburgh Library System search strategies and reveal that APDs, particularly those with dopamine<sub>2</sub> (D<sub>2</sub>) receptor antagonism, generally impair the recovery process in rodents of both sexes and, in some instances, attenuate the potential benefits of neurorehabilitation. We believe that the compilation of findings represented by this exhaustive review of pre-clinical TBI + APD models can serve as a convenient source for guiding informed decisions by critical care clinicians and physiatrists contemplating APD use for patients exhibiting agitation.</p>","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":"4 1","pages":"724-735"},"PeriodicalIF":1.8,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10621671/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71489695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association Between High-Level D-Dimer at Admission and Early Intubation in Patients With Moderate Traumatic Brain Injury. 中度颅脑损伤患者入院时高水平D-二聚体与早期插管之间的关系。
Q3 CLINICAL NEUROLOGY Pub Date : 2023-10-25 eCollection Date: 2023-01-01 DOI: 10.1089/neur.2023.0068
Qi Zhang, Hong Min Kuang, Du Juan Qiao, Xiang Lin Zhong, Jia Jia Kang, Rui Na Ma, Min Li

It is unclear who can benefit from tracheal intubation in the moderate (mTBI) traumatic brain injury (TBI) population. Given that mTBI patients are conscious, intubation can cause intense stress, possibly triggering neurological deterioration. Therefore, identifying potential risk factors for intubation in mTBI patients can serve as a valuable clinical warning. We sought to investigate whether elevated D-dimer is a possible risk factor for intubation in mTBI patients. Using the STROBE statement, adult patients with isolated TBI (Glasgow Coma Scale [GCS] score 9-13) treated at a high-volume neurotrauma center between January 2015 and December 2020 were reviewed. The demographics, clinical presentation, neuroimaging, and laboratory information were collected based on the patients' electronic medical record. D-dimer values were assessed from serum when patients were admitted to the hospital. The primary study end-point was that the mTBI patient was intubated within 72 h upon admission. A total of 557 patients with mTBI were finally included in this study. Of these, 85 (15.3%) patients were intubated. Multi-variate logistic regression analysis showed that high-level D-dimer (≥17.9mg/L) was significantly associated with early tracheal intubation in mTBI patients (odds ratio, 3.10 [1.16-8.25]; p = 0.024) after adjusting for age, sex, GCS scores, Marshall scores, and Injury Severity Scores. Sensitivity analysis showed that high-level D-dimer had a robust correlation with intubation in the different subgroups or after propensity score matching. High-level D-dimer on admission is an independent risk factor for early tracheal intubation in isolated mTBI patients.

目前尚不清楚在中度(mTBI)创伤性脑损伤(TBI)人群中,谁能从气管插管中受益。考虑到mTBI患者是有意识的,插管可能会引起强烈的压力,可能会引发神经系统恶化。因此,识别mTBI患者插管的潜在危险因素可以作为一个有价值的临床警告。我们试图研究D-二聚体升高是否是mTBI患者插管的可能风险因素。使用STROBE声明,回顾了2015年1月至2020年12月期间在高容量神经创伤中心接受治疗的患有孤立性TBI(格拉斯哥昏迷量表[GCS]评分9-13)的成年患者。人口统计学、临床表现、神经影像学和实验室信息是根据患者的电子病历收集的。当患者入院时,从血清中评估D-二聚体值。主要研究终点是mTBI患者在72小时内插管 h入院时。本研究最终纳入了557名mTBI患者。其中,85名(15.3%)患者接受了插管治疗。多变量逻辑回归分析显示,高水平D-二聚体(≥17.9mg/L)与mTBI患者的早期气管插管显著相关(比值比3.10[1.6-8.25];p = 0.024)。敏感性分析显示,在不同亚组或倾向评分匹配后,高水平的D-二聚体与插管有着密切的相关性。入院时高水平的D-二聚体是孤立mTBI患者早期气管插管的独立危险因素。
{"title":"Association Between High-Level D-Dimer at Admission and Early Intubation in Patients With Moderate Traumatic Brain Injury.","authors":"Qi Zhang,&nbsp;Hong Min Kuang,&nbsp;Du Juan Qiao,&nbsp;Xiang Lin Zhong,&nbsp;Jia Jia Kang,&nbsp;Rui Na Ma,&nbsp;Min Li","doi":"10.1089/neur.2023.0068","DOIUrl":"https://doi.org/10.1089/neur.2023.0068","url":null,"abstract":"<p><p>It is unclear who can benefit from tracheal intubation in the moderate (mTBI) traumatic brain injury (TBI) population. Given that mTBI patients are conscious, intubation can cause intense stress, possibly triggering neurological deterioration. Therefore, identifying potential risk factors for intubation in mTBI patients can serve as a valuable clinical warning. We sought to investigate whether elevated D-dimer is a possible risk factor for intubation in mTBI patients. Using the STROBE statement, adult patients with isolated TBI (Glasgow Coma Scale [GCS] score 9-13) treated at a high-volume neurotrauma center between January 2015 and December 2020 were reviewed. The demographics, clinical presentation, neuroimaging, and laboratory information were collected based on the patients' electronic medical record. D-dimer values were assessed from serum when patients were admitted to the hospital. The primary study end-point was that the mTBI patient was intubated within 72 h upon admission. A total of 557 patients with mTBI were finally included in this study. Of these, 85 (15.3%) patients were intubated. Multi-variate logistic regression analysis showed that high-level D-dimer (≥17.9mg/L) was significantly associated with early tracheal intubation in mTBI patients (odds ratio, 3.10 [1.16-8.25]; <i>p</i> = 0.024) after adjusting for age, sex, GCS scores, Marshall scores, and Injury Severity Scores. Sensitivity analysis showed that high-level D-dimer had a robust correlation with intubation in the different subgroups or after propensity score matching. High-level D-dimer on admission is an independent risk factor for early tracheal intubation in isolated mTBI patients.</p>","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":"4 1","pages":"715-723"},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric Traumatic Brain Injury in the Middle East and North Africa Region: A Systematic Review and Meta-Analysis to Assess Characteristics, Mechanisms, and Risk Factors. 中东和北非地区儿童创伤性脑损伤:评估特征、机制和危险因素的系统回顾和元分析。
IF 1.8 Q3 CLINICAL NEUROLOGY Pub Date : 2023-10-17 eCollection Date: 2023-01-01 DOI: 10.1089/neur.2023.0007
Samar Al-Hajj, Sarah H Farran, Batoul Dekmak, Layal Hneiny, Hussein Abou Abbas, Aya Hassoun, Nadine Youness, Sarah Ghalayini, Nour Abou Khalil, Fiona Lecky, Shima Shahjouieh, Layal Ghamlouche, Zainab Nasrallah, Firas Kobeissy

Pediatric traumatic brain injury (pTBI) represents a major cause of child injuries in the Middle East and North Africa (MENA) region. This review aims to assess pTBIs in the MENA region and reports their clinical severity and outcomes. A search was conducted using major electronic databases, including Medline/Ovid, PubMed, EMBASE, Web of Science, and SCOPUS. Abstracts were screened independently and in duplicate to detect original research. The objective and study findings for each article were recorded, along with the mechanism of pTBI, patient age and sex, injury assessment tool(s) used, and outcome. A total of 1345 articles were retrieved, of which 152 met the criteria for full-text review, and 32 were included in this review. Males predominantly suffered from pTBIs (78%). Motor vehicle accidents, followed by child abuse, were the leading causes of pTBI. Overall, 0.39% of cases were mild, 0.58% moderate, 16.25% severe, and 82.27% unclassified. The mortality rate was 13.11%. Most studies used the computed tomography scan, Glasgow Coma Scale, Abbreviated Injury Scale, and Injury Severity Score as investigation methods. This review reports on the alarming rate of child-abuse-related pTBI and offers further understanding of pTBI-associated risk factors and insight into the development of strategies to reduce their occurrence, as well as policies to promote child well-being.

儿童创伤性脑损伤(pTBI)是中东和北非(MENA)地区儿童损伤的主要原因。本综述旨在评估中东和北非地区的pTBI,并报告其临床严重程度和结果。使用主要的电子数据库进行搜索,包括Medline/Ovid、PubMed、EMBASE、Web of Science和SCOPUS。摘要是独立筛选的,一式两份,以检测原始研究。记录每篇文章的目的和研究结果,以及pTBI的机制、患者年龄和性别、使用的损伤评估工具和结果。共检索到1345篇文章,其中152篇符合全文审查标准,32篇被纳入本次审查。雄性主要患有pTBI(78%)。机动车事故,其次是虐待儿童,是pTBI的主要原因。总体而言,0.39%的病例为轻度,0.58%为中度,16.25%为重度,82.27%为未分类。死亡率为13.11%。大多数研究使用计算机断层扫描、格拉斯哥昏迷量表、缩写损伤量表和损伤严重程度评分作为调查方法。这篇综述报告了与儿童虐待相关的pTBI的惊人比率,并进一步了解了与pTBI相关的风险因素,深入了解了减少其发生的策略以及促进儿童福祉的政策的制定。
{"title":"Pediatric Traumatic Brain Injury in the Middle East and North Africa Region: A Systematic Review and Meta-Analysis to Assess Characteristics, Mechanisms, and Risk Factors.","authors":"Samar Al-Hajj, Sarah H Farran, Batoul Dekmak, Layal Hneiny, Hussein Abou Abbas, Aya Hassoun, Nadine Youness, Sarah Ghalayini, Nour Abou Khalil, Fiona Lecky, Shima Shahjouieh, Layal Ghamlouche, Zainab Nasrallah, Firas Kobeissy","doi":"10.1089/neur.2023.0007","DOIUrl":"10.1089/neur.2023.0007","url":null,"abstract":"<p><p>Pediatric traumatic brain injury (pTBI) represents a major cause of child injuries in the Middle East and North Africa (MENA) region. This review aims to assess pTBIs in the MENA region and reports their clinical severity and outcomes. A search was conducted using major electronic databases, including Medline/Ovid, PubMed, EMBASE, Web of Science, and SCOPUS. Abstracts were screened independently and in duplicate to detect original research. The objective and study findings for each article were recorded, along with the mechanism of pTBI, patient age and sex, injury assessment tool(s) used, and outcome. A total of 1345 articles were retrieved, of which 152 met the criteria for full-text review, and 32 were included in this review. Males predominantly suffered from pTBIs (78%). Motor vehicle accidents, followed by child abuse, were the leading causes of pTBI. Overall, 0.39% of cases were mild, 0.58% moderate, 16.25% severe, and 82.27% unclassified. The mortality rate was 13.11%. Most studies used the computed tomography scan, Glasgow Coma Scale, Abbreviated Injury Scale, and Injury Severity Score as investigation methods. This review reports on the alarming rate of child-abuse-related pTBI and offers further understanding of pTBI-associated risk factors and insight into the development of strategies to reduce their occurrence, as well as policies to promote child well-being.</p>","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":"4 1","pages":"693-714"},"PeriodicalIF":1.8,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615069/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polyurethane Culture Substrates Enable Long-Term Neuron Monoculture in a Human in vitro Model of Neurotrauma. 聚氨酯培养基能够在人类体外神经创伤模型中长期单核培养神经元。
Q3 CLINICAL NEUROLOGY Pub Date : 2023-10-16 eCollection Date: 2023-01-01 DOI: 10.1089/neur.2023.0060
Angela Mitevska, Citlally Santacruz, Eric J Martin, Ian E Jones, Arian Ghiacy, Simon Dixon, Nima Mostafazadeh, Zhangli Peng, Evangelos Kiskinis, John D Finan

Human induced pluripotent stem cell (hiPSC)-derived cells can reproduce human-specific pathophysiology, patient-specific vulnerability, and gene-environment interactions in neurological disease. Human in vitro models of neurotrauma therefore have great potential to advance the field. However, this potential cannot be realized until important biomaterials challenges are addressed. Status quo stretch injury models of neurotrauma culture cells on sheets of polydimethylsiloxane (PDMS) that are incompatible with long-term monoculture of hiPSC-derived neurons. Here, we overcame this challenge in an established human in vitro neurotrauma model by replacing PDMS with a highly biocompatible form of polyurethane (PU). This substitution allowed long-term monoculture of hiPSC-derived neurons. It also changed the biomechanics of stretch injury. We quantified these changes experimentally using high-speed videography and digital image correlation. We used finite element modeling to quantify the influence of the culture substrate's thickness, stiffness, and coefficient of friction on membrane stretch and concluded that the coefficient of friction explained most of the observed biomechanical changes. Despite these changes, we demonstrated that the modified model produced a robust, dose-dependent trauma phenotype in hiPSC-derived neuron monocultures. In summary, the introduction of this PU film makes it possible to maintain hiPSC-derived neurons in monoculture for long periods in a human in vitro neurotrauma model. In doing so, it opens new horizons in the field of neurotrauma by enabling the unique experimental paradigms (e.g., isogenic models) associated with hiPSC-derived neurons.

人类诱导多能干细胞(hiPSC)衍生的细胞可以在神经疾病中复制人类特异性的病理生理学、患者特异性的脆弱性和基因与环境的相互作用。因此,神经创伤的人类体外模型在该领域具有巨大的发展潜力。然而,在重要的生物材料挑战得到解决之前,这种潜力是无法实现的。聚二甲基硅氧烷(PDMS)片上神经创伤培养细胞的拉伸损伤模型现状,该模型与长期单一培养的hiPSC衍生神经元不相容。在这里,我们通过用高度生物相容性的聚氨酯(PU)代替PDMS,在已建立的人类体外神经损伤模型中克服了这一挑战。这种替代允许长期单一培养hiPSC衍生的神经元。它还改变了拉伸损伤的生物力学特性。我们使用高速摄像和数字图像相关技术对这些变化进行了实验量化。我们使用有限元建模来量化培养基的厚度、刚度和摩擦系数对膜拉伸的影响,并得出结论,摩擦系数解释了大多数观察到的生物力学变化。尽管有这些变化,我们还是证明了改良模型在hiPSC衍生的神经元单一培养中产生了强大的、剂量依赖性的创伤表型。总之,这种PU膜的引入使得在人类体外神经损伤模型中长期单一培养hiPSC衍生的神经元成为可能。通过这样做,它通过实现与hiPSC衍生神经元相关的独特实验范式(例如,等基因模型),在神经损伤领域开辟了新的视野。
{"title":"Polyurethane Culture Substrates Enable Long-Term Neuron Monoculture in a Human <i>in vitro</i> Model of Neurotrauma.","authors":"Angela Mitevska, Citlally Santacruz, Eric J Martin, Ian E Jones, Arian Ghiacy, Simon Dixon, Nima Mostafazadeh, Zhangli Peng, Evangelos Kiskinis, John D Finan","doi":"10.1089/neur.2023.0060","DOIUrl":"10.1089/neur.2023.0060","url":null,"abstract":"<p><p>Human induced pluripotent stem cell (hiPSC)-derived cells can reproduce human-specific pathophysiology, patient-specific vulnerability, and gene-environment interactions in neurological disease. Human <i>in vitro</i> models of neurotrauma therefore have great potential to advance the field. However, this potential cannot be realized until important biomaterials challenges are addressed. <i>Status quo</i> stretch injury models of neurotrauma culture cells on sheets of polydimethylsiloxane (PDMS) that are incompatible with long-term monoculture of hiPSC-derived neurons. Here, we overcame this challenge in an established human <i>in vitro</i> neurotrauma model by replacing PDMS with a highly biocompatible form of polyurethane (PU). This substitution allowed long-term monoculture of hiPSC-derived neurons. It also changed the biomechanics of stretch injury. We quantified these changes experimentally using high-speed videography and digital image correlation. We used finite element modeling to quantify the influence of the culture substrate's thickness, stiffness, and coefficient of friction on membrane stretch and concluded that the coefficient of friction explained most of the observed biomechanical changes. Despite these changes, we demonstrated that the modified model produced a robust, dose-dependent trauma phenotype in hiPSC-derived neuron monocultures. In summary, the introduction of this PU film makes it possible to maintain hiPSC-derived neurons in monoculture for long periods in a human <i>in vitro</i> neurotrauma model. In doing so, it opens new horizons in the field of neurotrauma by enabling the unique experimental paradigms (e.g., isogenic models) associated with hiPSC-derived neurons.</p>","PeriodicalId":74300,"journal":{"name":"Neurotrauma reports","volume":"4 1","pages":"682-692"},"PeriodicalIF":0.0,"publicationDate":"2023-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71429951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neurotrauma reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1